Last 32 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.55 | 2.15 | 7.21 | 5.75 | 8.31 | 4.05 | 1.64 | 3.10 | 4.47 | 4.34 | 5.13 | 2.03 | 1.27 | 2.27 | 2.07 | 1.11 | 1.24 | 8.84 | 6.07 | 22.68 | 39.63 |
| — | -46.7% | +339.7% | +85.5% | +85.8% | -6.8% | -68.0% | +52.4% | +251.3% | +91.2% | +147.5% | +83.4% | +2.9% | -74.3% | -65.8% | -95.1% | -96.9% | -92.9% | — | — | — | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.18 | 3.90 | 3.61 | 5.30 | 6.94 | 9.29 | 11.13 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -39.7% | -58.1% | -67.6% | -30.8% | +10.4% | +26.9% | +78.9% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 48.65 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 28.55 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.6% | 87.8% | 82.0% | 92.6% | 92.7% | 95.6% | 91.1% | 91.9% | 95.4% | 93.0% | 86.1% | -645.4% | 97.5% | 94.1% | 100.1% | 99.3% | 98.3% | 86.9% | 98.9% | 95.5% | 96.2% |
| — | -8.1% | -10.0% | +0.8% | -2.8% | +2.7% | +5.8% | +114.2% | -2.1% | -1.2% | -14.0% | -749.9% | -0.8% | +8.3% | +1.3% | +4.0% | +2.2% | -10.2% | — | — | — | |
| Operating Margin | -133.2% | -132.0% | -126.0% | -78.6% | -184.6% | -234.3% | -123.6% | -191.8% | -192.6% | -166.8% | -186.2% | -238.1% | -258.1% | -205.6% | -264.4% | -15.4% | -4.1% | -401.4% | -86.8% | -369.1% | -439.6% |
| — | +43.7% | -2.0% | +59.0% | +4.2% | -40.5% | +33.6% | +19.4% | +25.4% | +18.9% | +29.6% | -1447.7% | -6225.4% | +48.8% | -204.6% | +95.8% | +99.1% | +78.6% | — | — | — | |
| Net Margin | -175.3% | -86.1% | -164.6% | -27.8% | -249.4% | -300.7% | -167.6% | -181.7% | -238.1% | -209.9% | -258.2% | -506.4% | -329.9% | -253.7% | -312.6% | -34.6% | -66.3% | -372.3% | -35.8% | -202.1% | -544.2% |
| — | +71.4% | +1.8% | +84.7% | -4.7% | -43.2% | +35.1% | +64.1% | +27.8% | +17.3% | +17.4% | -1363.3% | -397.5% | +31.9% | -772.5% | +82.9% | +87.8% | +80.7% | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — | -336.3% | -101.4% | -26.2% | -46.0% | -46.3% | -10.1% | -19.5% | -33.2% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -626.1% | -900.2% | -34.8% | -38.6% | -72.9% | +37.7% | -23.8% | -367.2% | |
| ROA | -44.2% | -5.8% | -10.7% | -2.1% | -13.4% | -19.1% | -13.0% | -9.2% | -12.2% | -10.8% | -14.1% | -20.7% | -9.8% | -10.0% | -12.4% | -4.7% | -9.6% | -11.7% | -2.8% | -5.5% | -13.0% |
| — | +69.6% | +17.4% | +77.2% | -9.9% | -77.4% | +7.7% | +55.8% | -24.3% | -7.1% | -13.5% | -338.1% | -2.0% | +14.1% | -346.1% | +13.7% | +25.9% | +25.5% | +73.7% | +49.3% | -185.9% | |
| ROIC | — | — | — | — | — | — | -125.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 3.26 | 1.63 | 1.11 | 0.90 | 0.63 | 0.84 | 0.54 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | +417.5% | +94.3% | +107.2% | +119.7% | +293.0% | +145.2% | +404.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.37 | 3.03 | 4.09 | 4.37 | 4.63 | 4.93 | 4.46 | 3.82 | 4.92 | 6.17 | 4.61 | 4.97 | 4.80 | 5.12 | 4.69 | 5.31 | 5.00 | 5.76 | 6.89 | 7.10 | 9.59 |
| — | -38.6% | -8.3% | +14.3% | -5.9% | -20.0% | -3.1% | -23.1% | +2.5% | +20.4% | -1.7% | -6.4% | -4.0% | -11.1% | -32.0% | -25.3% | -47.8% | -24.8% | -27.5% | -36.2% | -38.4% | |
| Quick Ratio | 4.31 | 2.97 | 4.02 | 4.31 | 4.34 | 4.66 | 4.16 | 3.59 | 4.68 | 5.90 | 4.35 | 4.73 | 4.51 | 4.88 | 4.46 | 5.16 | 4.82 | 5.56 | 6.72 | 6.95 | 9.45 |
| — | -36.2% | -3.4% | +19.9% | -7.4% | -21.1% | -4.4% | -24.1% | +3.8% | +20.9% | -2.4% | -8.3% | -6.4% | -12.2% | -33.6% | -25.8% | -49.0% | -25.9% | -29.2% | -37.6% | -39.2% | |
| Interest Coverage | -1.77 | -3.40 | -1.67 | 0.48 | -2.06 | -3.26 | -2.17 | -1.65 | -2.33 | -1.82 | -2.66 | -5.21 | -2.61 | -4.11 | -4.59 | -1.29 | -3.52 | -6.42 | -0.93 | -4.92 | -15.22 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 32 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ADCT stock.
ADC Therapeutics S.A.'s current P/E is -2.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
ADC Therapeutics S.A.'s current operating margin is -133.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ADC Therapeutics S.A.'s business trajectory between earnings reports.